# TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule

> **NCT00752648** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C
- HCV

## Interventions

- **DRUG:** TMC435350

## Key facts

- **NCT ID:** NCT00752648
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752648, "TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00752648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*